Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:58 PM
Ignite Modification Date:
2025-12-24 @ 2:58 PM
NCT ID:
NCT06830759
Eligibility Criteria:
Inclusion Criteria:
* Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
* Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
* The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
Exclusion Criteria:
* Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
* Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06830759
Study Brief:
Protocol Section:
NCT06830759